<DOC>
	<DOCNO>NCT02669264</DOCNO>
	<brief_summary>This study evaluate ADCT-402 patient relapse refractory B-cell lineage acute lymphoblastic leukemia ( B-ALL ) . Patients participate dose-escalation phase ( Part 1 ) dose expansion ( Part 2 ) . In Part 2 , patient receive dose level identify Part 1 .</brief_summary>
	<brief_title>Study ADCT-402 Patients With Relapsed Refractory B-cell Lineage Acute Lymphoblastic Leukemia ( B-ALL )</brief_title>
	<detailed_description>Study ADCT-402-102 first clinical study ADCT-402 patient B-cell lineage acute lymphoblastic leukemia ( ALL ) . ADCT-402 antibody drug conjugate ( ADC ) compose humanize antibody direct human cluster differentiation 19 ( CD19 ) , stochastically conjugate via valine-alanine cleavable , maleimide linker pyrrolobenzodiazepine ( PBD ) dimer cytotoxin . The study conduct 2 part . In Part 1 ( dose escalation ) patient receive infusion ADCT-402 , escalate dos . Part 1 continue maximum tolerate dose determine . In Part 2 ( expansion ) , patient assign recommended dose level ADCT-402 identify Part 1 Dose Escalation Steering Committee . For patient , study include screen period ( 28 day ) , treatment period ( withdrawal ) , follow-up period ass disease progression survival 12 month last dose study drug . The total study duration dependent overall patient tolerability study drug response treatment . It anticipate duration entire study ( Parts 1 2 ) could approximately 3 year first patient treat last patient complete .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<criteria>Male female patient , age 12 year old , relapse refractory BALL fail , intolerant , establish therapy ; treatment option available . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . Serum creatinine ≤1.5mg/dL . Serum alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤2 time upper limit normal ( ULN ) ; ≤5 time ULN liver bone involvement . Total serum bilirubin ≤1.5 time ULN . Negative urine serum betahuman chorionic gonadotropin ( βHCG ) pregnancy test within 7 day prior Cycle 1 , Day 1 visit , woman childbearing potential . Males , female patient biologically capable child , must agree use medically acceptable method birth control . Patients option treatment BALL current state disease . Known active central nervous system ( CNS ) leukemia . Patients Burkitt 's leukemia/lymphoma . Active graftversushost disease . Autologous allogenic transplant within 60 day prior Screening . Known history immunogenicity hypersensitivity CD19 antibody . Known history positive serum human ADA . Active autoimmune disease , motor neuropathy consider autoimmune origin , central nervous system autoimmune disease . Known seropositive human immunodeficiency ( HIV ) virus , hepatitis B surface antigen ( HbsAg ) , antibody hepatitis C virus ( antiHCV ) . History StevensJohnson syndrome toxic epidermal necrolysis syndrome . Pregnant breastfeed woman . Significant medical comorbidities , include uncontrolled hypertension ( diastolic blood pressure &gt; 115 mm Hg ) , unstable angina , congestive heart failure ( great New York Heart Association class II ) , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia , poorly control diabetes , severe chronic pulmonary disease , coronary angioplasty , myocardial infarction within 6 month prior Screening , uncontrolled atrial ventricular cardiac arrhythmia . Use experimental medication ( ) within 21 day prior Cycle 1 , Day 1 visit . Major surgery , chemotherapy , systemic therapy ( exclude hydroxyurea steroid ) , radiotherapy , biotherapy target therapy within 21 day prior Cycle 1 , Day 1 visit . Failure recover acute non hematologic toxicity ( except alopecia ) , due previous therapy , prior Screening . Isolated extramedullary relapse . Congenital long QT syndrome correct QTc interval ≥450 m Screening visit . Active second primary malignancy nonmelanoma skin cancer , nonmetastatic prostate cancer , situ cervical cancer , ductal lobular carcinoma situ breast , malignancy determine exclusionary . Any significant medical illness , abnormality , condition would make patient inappropriate study participation put patient risk .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>